What were Ipca Laboratories Ltd's latest quarterly results?
Ipca Laboratories Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +31.9% (stable)
- Revenue Growth YoY: +6.5%
- Operating Margin: 22.0% (stable)
Ipca Laboratories Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +10.9%AverageRe-Entry
In , Ipca Laboratories Ltd (Pharma - Formulators) is outperforming Nifty 500 with +10.9% relative strength. Fundamentals: Average.
Ipca Laboratories Ltd Key Facts
- PE Ratio
- 37.3x
- Market Cap
- ₹39,390 Cr
- PAT Growth YoY
- +32%
- Revenue Growth YoY
- +7%
- OPM
- 22.0%
- RS vs Nifty 500
- +10.9%
PE: Mid ContractionStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
👔Promoter stake down 1.6% this quarter
🏛️DII accumulation — stake up 2.6%
💰Trading 45% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
+32%
Stable
Revenue YoY
+7%
Decelerating
Operating Margin
22.0%
+100 bps YoY
PE Ratio
37.3
Current Price
₹1,553
Dividend Yield
0.26%
Fundamental Score
55/100
Average
3Y PAT CAGR
-4%
Market Cap
39.4K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Ipca Laboratories Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +7% | +15% | Decelerating |
| PAT (Net Profit) | +32% | -4% | Stable |
| OPM | 22.0% | +100 bps | Stable |
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Ipca Laboratories Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Ipca Laboratories Ltd's profit growing or declining?
Ipca Laboratories Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +31.9% (latest quarter)
- PAT Growth QoQ: +29.5% (sequential)
- 3-Year PAT CAGR: -4.1%
- Trend: Stable — consistent growth pattern
What is Ipca Laboratories Ltd's revenue growth trend?
Ipca Laboratories Ltd's revenue growth trend is decelerating.
- Revenue Growth YoY: +6.5%
- Revenue Growth QoQ: -6.4% (sequential)
- 3-Year Revenue CAGR: +15.3%
How is Ipca Laboratories Ltd's operating margin trending?
Ipca Laboratories Ltd's operating margin is stable.
- Current OPM: 22.0%
- OPM Change YoY: +1.0% basis points
- OPM Change QoQ: +1.0% basis points
What is Ipca Laboratories Ltd's 3-year profit and revenue CAGR?
Ipca Laboratories Ltd's long-term compounding rates
- 3-Year Profit CAGR: -4.1%
- 3-Year Revenue CAGR: +15.3%
Is Ipca Laboratories Ltd's growth accelerating or decelerating?
Ipca Laboratories Ltd's earnings growth is stable with positive momentum on a sequential basis.
- YoY Acceleration: +17.7% bps
- Sequential Acceleration: +8.9% bps
What is Ipca Laboratories Ltd's trailing twelve month (TTM) performance?
Ipca Laboratories Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹942 Cr
- TTM PAT Growth: +30.5% YoY
- TTM Revenue: ₹10,000 Cr
- TTM Revenue Growth: +8.9% YoY
- TTM Operating Margin: 20.1%
Is Ipca Laboratories Ltd overvalued or undervalued?
Ipca Laboratories Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 37.3x
- Price-to-Book: 5.3x
What is Ipca Laboratories Ltd's current PE ratio?
Ipca Laboratories Ltd's current PE ratio is 37.3x.
- Current PE: 37.3x
- Market Cap: 39.4K Cr
- Dividend Yield: 0.26%
How does Ipca Laboratories Ltd's valuation compare to its history?
Ipca Laboratories Ltd's current PE is 37.3x.
- Current PE: 37.3x
- Valuation Assessment: Significantly Overvalued
What is Ipca Laboratories Ltd's price-to-book ratio?
Ipca Laboratories Ltd's price-to-book ratio is 5.3x.
- Price-to-Book (P/B): 5.3x
- Book Value per Share: ₹293
- Current Price: ₹1553
Is Ipca Laboratories Ltd a fundamentally strong company?
Ipca Laboratories Ltd is rated Average with a fundamental score of 54.78/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +6.5% (10% weight)
- PAT Growth YoY: +31.9% (10% weight)
- PAT Growth QoQ: +29.5% (10% weight)
- Margins stable (10% weight)
Is Ipca Laboratories Ltd debt free?
Ipca Laboratories Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹1,000 Cr
What is Ipca Laboratories Ltd's return on equity (ROE) and ROCE?
Ipca Laboratories Ltd's return ratios over recent years
- FY2023: ROCE 11.0%
- FY2024: ROCE 13.0%
- FY2025: ROCE 15.0%
Is Ipca Laboratories Ltd's cash flow positive?
Ipca Laboratories Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹1,000 Cr
- Free Cash Flow (FCF): ₹451 Cr
- CFO/PAT Ratio: 168% (strong cash conversion)
What is Ipca Laboratories Ltd's dividend yield?
Ipca Laboratories Ltd's current dividend yield is 0.26%.
- Dividend Yield: 0.26%
- Current Price: ₹1553
Who holds Ipca Laboratories Ltd shares — promoters, FII, DII?
Ipca Laboratories Ltd's shareholding pattern (Mar 2026)
- Promoters: 44.7%
- FII (Foreign): 10.6%
- DII (Domestic): 37.1%
- Public: 7.2%
Is promoter holding increasing or decreasing in Ipca Laboratories Ltd?
Ipca Laboratories Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 44.7% (Mar 2026)
- Previous Quarter: 44.7% (Dec 2025)
- Change: 0.00% (stable)
How long has Ipca Laboratories Ltd been outperforming Nifty 500?
Ipca Laboratories Ltd has been outperforming Nifty 500 for 3 consecutive weeks, indicating early-stage outperformance.
Is Ipca Laboratories Ltd a new momentum entry or an established outperformer?
Ipca Laboratories Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Is Ipca Laboratories Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Ipca Laboratories Ltd may be worth studying
- Earnings growing at +31.9% YoY
- Cash flow is positive — CFO ₹1,000 Cr
What is the investment thesis for Ipca Laboratories Ltd?
Ipca Laboratories Ltd investment thesis summary:
Risk Factors (Bear Case)
- Appears significantly overvalued
What is the future outlook for Ipca Laboratories Ltd?
Ipca Laboratories Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: decelerating
- Margin Trend: stable
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.